SCHEMBL1383232

SCHEMBL1383232

CC(Oc1ccc(-n2cnc3cc(C(=O)NCC4CCOCC4)ccc32)cc1)C(C)Oc1ccccn1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.47
MAPT P10636 3/20 0.46
ALDH1A1 P00352 1/20 0.46
KMT2A Q03164 5/20 0.46
HPGD P15428 4/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TP53 P04637 5/20 0.46
MEN1 O00255 4/20 0.46
RAB9A P51151 1/20 0.45
NPC1 O15118 1/20 0.43
ACSS2 Q9NR19 1/20 0.41
LMNA P02545 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
FGFR1 P11362 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1379664 0.92 BRD4 (0.45) BRD4MAPTALDH1A1KMT2AHPGD
SCHEMBL1378612 0.92 BRD4 (0.45) BRD4MAPTALDH1A1KMT2AHPGD
SCHEMBL1379392 0.88 MAPT (0.46) BRD4MAPTALDH1A1KMT2AHPGD
SCHEMBL1382987 0.86 MEN1 (0.54) MAPTALDH1A1KMT2AHPGDTP53
SCHEMBL1378071 0.84 KMT2A (0.55) MAPTALDH1A1KMT2AHPGDTP53
SCHEMBL1379910 0.83 MAPT (0.51) MAPTALDH1A1KMT2AHPGDTP53
SCHEMBL1381184 0.83 RIPK1 (0.52) MAPTALDH1A1KMT2AHPGDTP53
SCHEMBL1381922 0.81 MEN1 (0.51) MAPTALDH1A1KMT2AHPGDTP53
SCHEMBL1382227 0.81 KMT2A (0.56) MAPTALDH1A1KMT2AHPGDTP53
SCHEMBL1378402 0.80 KMT2A (0.46) BRD4MAPTALDH1A1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4769720-B2 2011-09-07 JP claimed
US-20060189629-A1 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. 2006-08-24 US claimed
EP-1664021-A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS OSI Pharmaceuticals, Inc. (US) 2006-06-07 EP claimed
WO-2005021531-A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2005-03-10 WO claimed
US-7521448-B2 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-04-21 US disclosed
US-20060189629-A1 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. 2006-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189629-A1 N-substituted benzimidazolyl c-Kit inhibitors KIT, CHUK, TNNI3K BRD4 2603/4885MAPT 4641/4885ALDH1A1 430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.